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pt received February 20, 2his study sought to determine the clinical and biological signiﬁcance of elevated cardiac troponin T (cTnT) in
patients with neuromuscular diseases.Background Practice guidelines regard cTnT and cardiac troponin I (cTnI) as equally sensitive and speciﬁc for the diagnosis of
myocardial injury. Although cTnI is unique to myocardium, cTnT can be re-expressed in skeletal muscle in response
to injury. The commercial cTnT assay is claimed to be cardiac speciﬁc.Methods Fifty-two patients with 20 different types of acquired and inherited neuromuscular diseases underwent full clinical
assessment, cardiac investigations, and measurements of serum cTnT, cTnI, creatine kinase (CK), creatine kinase
myocardial band (CK-MB), and N-terminal pro-B–type natriuretic peptide (NT-proBNP).Results Serial measurements (265 samples) in 25 initially hospitalized patients taken during a mean of 2.4 years showed
persistent elevation of cTnT (median: 0.08 mg/l; interquartile range: 0.06 to 0.14 mg/l), CK (582 U/l; 303 to 3,662
U/l), and CK-MB (24 mg/l; 8 to 34 mg/l). In contrast, cTnI, measured using 2 sensitive assays, was persistently
normal throughout the study in 22 patients. Electrocardiograms (ECGs) and echocardiograms were normal in 16 and
17 patients, respectively, and no serial changes were observed. Therapeutic interventions in patients with reversible
myopathies normalized cTnT, CK, and CK-MB in unison. Single measurements in 27 ambulatory patients showed
elevated CK (953 U/l; 562 to 1,320 U/l), CK-MB (18 mg/l; 11 to 28 mg/l), and cTnT (0.03 mg/l; 0.02 to 0.05 mg/l) in
21, 22, and 18 patients respectively. cTnI was abnormal in only 1 patient. NT-proBNP (41 pg/ml; 35 to 97 pg/ml)
was normal in all but 2 patients. ECGs were normal in 15 patients. No patients with elevated cTnT, but with normal
cTnI, had any cardiovascular events in either group during follow-up.Conclusions Patients with a wide spectrum of neuromuscular diseases commonly have persistent elevation of cTnT and CK-MB
in the absence of clinical and cTnI evidence of myocardial injury. Re-expressed cTnT in diseased skeletal muscle
appears to be the source of the elevated cTnT detected in the circulation of these patients. (J Am Coll Cardiol
2014;63:2411–20) ª 2014 by the American College of Cardiology FoundationTroponin is a regulatory protein complex located on the thin
ﬁlament of striated muscles. It consists of 3 subunits: C, I,
and T. Troponins I and T have 3 isoforms, each controlled
by different genes; 1 is cardiac and the other 2 are slow
skeletal and fast skeletal isoforms. Cardiac troponin T
(cTnT) and cardiac troponin I (cTnI) have become the
biomarkers of choice for the diagnosis of acute myocardial
infarction (AMI), superceding the creatine kinase myocar-
dial band (CK-MB) (1–3). Elevation of either marker in
the circulation is generally interpreted as indicative ofscular Medicine, Wirral University Teaching
yDepartment of Laboratory Medicine, Wirral
United Kingdom; and zThe Walton Centre for
ol, United Kingdom. The authors have reported
t to the contents of this paper to disclose.
014; accepted March 4, 2014.myocardial necrosis. The third edition of the universal
deﬁnition of myocardial infarction (4), endorsed by the
European Society of Cardiology, the American Heart As-
sociation, the American College of Cardiology Foundation,
and the World Heart Federation, re-emphasizes the pre-
eminent diagnostic role of cardiac troponins and makes no
distinction between cTnT and cTnI. Similarly, the recent
American College of Cardiology Foundation recommen-
dations on the interpretation of elevated cardiac troponins
assume that the 2 biomarkers have equivalent diagnostic
accuracy for myocardial injury (5).
Our clinical experience with patients with neuromuscular
diseases led us to question the cardiac speciﬁcity of the
commercial cTnT immunoassay. We observed that these
patients commonly have elevated cTnT without any clini-
cally apparent evidence of myocardial injury. Although
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and Acronyms
AMI = acute myocardial
infarction
BMD = Becker muscular
dystrophy
CK = creatine kinase
CK-MB = creatine kinase
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cTnI = cardiac troponin I
cTnT = cardiac troponin T
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2412cTnT and cTnI are both absent
in healthy adult skeletal muscle,
cTnT, but not cTnI, is present
in fetal skeletal muscle (6–9).
When skeletal muscle is injured,
it repairs itself by regeneration,
a process that recapitulates em-
bryonic myogenesis (10,11). Re-
generating skeletal muscle thus
re-expresses fetal isoforms of
cTnT (12–15) and also CK-MB
(16–18). In contrast, cTnI has
not been shown to be expressed
in skeletal muscle at any point of
development (6). One study re-
ported the mRNA, but not the
protein, of cTnI in the skeletal
muscle of patients with Duchenne
muscular dystrophy (DMD) (19).
It is not known whether these
biological differences have any
signiﬁcant clinical implications.
We studied the behavior of cTnT
and cTnI in the circulation of
patients with several different
types of inherited and acquired
neuromuscular diseases. We usethe term “neuromuscular disease” to cover both primary my-
opathies and muscle diseases secondary to nerve disorders.Methods
Patients. The study started in 2005 when we observed
persistent elevation of cTnT and CK in patients with skel-
etal muscle diseases. The ﬁrst group consisted of 25 hospi-
talized patients (ages 58  17 years; range: 17 to 87 years)
admitted urgently to Wirral University Teaching Hospital
under the care of 1 cardiologist (D.R.). The hospital uses
both cTnT and CK routinely for the assessment of patients
suspected of having acute coronary syndromes.
Of these 25 patients, 13 had previously established di-
agnoses of neuromuscular diseases (3 facioscapulo humeral
muscle dystrophy, 2 polymyositis, 2 motor neurone disease,
2 paroxysmal rhabdomyolysis, 1 inclusion body myositis
[IBM], 1 muscle sarcoma, 1 myotonic dystrophy [MyoD],
1 periodic hypokalemic paralysis). The other 12 patients
received new diagnoses of skeletal myopathies (3 statin-
induced, 2 alcohol-induced, 1 inﬂammatory, 1 hypothyroid,
1 cocaine-induced, and 4 subclinical, presumed inﬂamma-
tory) during the course of this study.
To validate the ﬁndings in the hospitalized group, we
studied a second group consisting of 27 unselected ambu-
latory patients with different types of neuromuscular diseases
under routine follow-up in either a neuromuscular (n ¼ 19)
or cardiology (n ¼ 8) outpatient clinic. The clinical char-
acteristics of these 2 groups of patients are shown in Table 1.All patients underwent full clinical assessment and
routine blood tests consisting of full blood count, electro-
lytes, renal function, liver function, and thyroid function.
Cardiac investigations in hospitalized patients comprised
serial ECGs, echocardiograms, and when clinically indi-
cated, cardiac catheterization studies (coronary angiography,
left ventriculography, and pressure measurements). Serial
measurements of serum CK, CK-MB, cTnT, cTnI, and
N-terminal pro-B–type natriuretic peptide (NT-proBNP)
were performed while in hospital and also after discharge to
the outpatient clinic. ECG and echocardiography were also
repeated in the clinic at 4 to 6 monthly intervals. Ambula-
tory patients had single measurements of these biomakers
in addition to ECGs and echocardiograms. The study was
approved by the local research ethics committee, and pa-
tients gave written informed consent.
Cardiac troponin immunoassays. Roche Diagnostics
(Indiana, Indianapolis) is the sole manufacturer of cTnT as-
says. Serum cTnT was measured initially using the standard
third- and fourth-generation assays, and subsequently by the
high-sensitivity (hs-cTnT) assay when it became commer-
cially available. The standard assay has a limit of detection of
0.01 mg/l, a 99th percentile of<0.01 mg/l, and a coefﬁcient of
variation of 10% at 0.03mg/l. The corresponding values for the
hs-cTnT assay are 0.005, 0.014, and 0.013 mg/l (20).
Serum cTnI wasmeasured using 2 immunoassays, Siemens
cTnI-Ultra (Siemens Corporation, Washington, DC) and
Roche troponin I. The cTnI-Ultra assay has a limit of
detection of 0.006 mg/l, a 99th percentile of 0.04 mg/l, and a
10% coefﬁcient of variation at 0.03 mg/l. The corresponding
values for the Roche I assay are 0.10, 0.16, and 0.30 mg/l, as
obtained from the manufacturer’s package insert.
To ascertain that the cTnI-Ultra assay is at least as sen-
sitive as the conventional cTnT assay for the detection of
relatively minor myocardial injury, serum samples with low
concentrations of cTnT (median cTnT 0.14 mg/l; inter-
quartile range 0.06 to 0.33) from 32 randomly selected
patients with unequivocal AMI were analyzed. cTnI-Ultra
was elevated (>0.04 mg/l) in 31 patients. One patient
with cTnT of 0.03 mg/l had a cTnI-Ultra of 0.02 mg/l.
Regression analysis yielded the following relationship:
cTnI-Ultra ¼ 13.32 cTnT – 0.70 (r ¼ 0.89, p < 0.0001).
Serum CK-MB and NT-proBNP concentrations were
measured using Roche Diagnostics immunoassays. CK was
considered normal if <170 U/l in women and <200 U/l
in men.
All assays were performed according to the manufacturers’
instructions by experienced laboratory personnel blinded to
the study.
Statistical analysis. Continuous variables are reported as
medians with interquartile ranges or as means with SDs.Results
Hospitalized patients (n [ 25). Table 2 summarizes the
clinical presentation and results of investigations of the
Table 1 Clinical Characteristics of Patients
Characteristics
Hospitalized
(n ¼ 25)
Ambulatory
(n ¼ 27)
Age, yrs 58  17 49  14
Males 12 (48%) 23 (85%)
Hypertension 3 (12%) 6 (22%)
Diabetes 1 (4%) 2 (7%)
Chronic kidney disease 0 0
Statin therapy 12 (48%) 1 (4%)
Coronary artery disease 5 (20%) 1 (4%)
Previous myocardial infarction 1 (4%) 1 (4%)
Previous PCI or CABG 1 (4%) 0
Valvular heart disease 1 (4%) 0
Cardiac failure 2 (8%) 1 (4%)
Serum creatinine, mg/dl
Median 0.70 0.57
IQR 0.55–0.89 0.45–0.74
Values are mean  SD, n (%), median, or IQR.
CABG ¼ coronary artery bypass graft; IQR ¼ interquartile range; PCI ¼ percutaneous coronary
intervention.
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241325 patients. Fifteen patients were referred with an initial
diagnosis of acute coronary syndromes, of whom only 1 had
acute ischemic ECG changes. The other 10 patients had
no cardiac symptoms or ischemic ECG changes. ECGs
and echocardiograms were normal in 15 and 17 patients,
respectively. Cardiac catheterization studies were performed
on 15 occasions in 10 patients, 9 of whom presented with
chest pain. Cardiac catheterization was deemed to be clini-
cally inappropriate in the other 15 patients. Coronary an-
giograms were normal on 12 occasions in 7 patients. Left
ventriculograms and left ventricular end-diastolic pressures
were normal on 13 occasions in 9 patients. After initial
hospital discharge, further ECGs and echocardiograms were
performed, either in the outpatient clinic or through re-
admission in 21 and 17 patients, respectively. No patient
had new ECG or echocardiographic changes.
Despite the several different types of chronic injury to
skeletal muscle in this group, the observed biochemical
response was the same in almost all patients. Serial mea-
surements before any therapeutic interventions showed
persistent elevation of cTnT (0.08 mg/l; 0.04 to 0.13 mg/l),
CK (500 U/l; 177 to 3,100 U/l), and CK-MB (15 mg/l;
8 to 33 mg/l). These results are the medians and interquartile
ranges of the medians for each patient. In complete contrast,
cTnI was below the 99th percentile or even below the
detection limit in 22 patients. In 2 patients with severe left
ventricular dysfunction and a history of cardiac failure, all 4
biomarkers were persistently elevated. In a third patient with
mitral valve replacement and atrial ﬁbrillation, cTnI was just
above the upper reference limit, at 0.05 mg/l. In
all 3 patients, the elevated cTnI was noted to be dispro-
portionately low compared with cTnT, as shown in Table 2.
One patient with IBM was admitted with acute chest pain
and ST elevation. Although the diagnosis of AMI was
not in doubt, the admission values of cTnT (0.19 mg/l),
cTnI (0.62 mg/l), and CK (1333 U/l) were discordant. Thesemarkers were rechecked 4 weeks later when serial cTnI
was found to be persistently negative, but cTnT (mean
0.12 mg/l) and CK (mean 895 U/l) remained persistently
elevated.
Two patients triggered our interest and led us to
conduct this study. Over a 3-year period, patient #1 had
multiple admissions with chest pain and alcohol abuse.
ECGs (>70) and echocardiograms were normal. Her
cTnT (0.13 mg/l; 0.06 to 0.22 mg/l) and CK (2,699 U/l;
1,457 to 5,193 U/l) were found to be elevated on 49 oc-
casions. Her initial coronary angiogram showed a moderate
stenosis in the mid left anterior descending artery. Despite
stent placement, her admissions to hospital with chest pain
and cTnT elevation continued. Further coronary angiog-
raphy showed no obstructive disease, including a fully
patent left anterior descending artery. Patient #2 also had
multiple admissions with chest pain over a 7-year period.
Cardiac investigations, including cardiac catheterization
studies performed on 3 occasions, were normal. Her CK
(314 U/l; 115 to 481 U/l) and cTnT (0.14 mg/l; 0.11 to
0.20 mg/l) were elevated on 70 occasions. In these 2 pa-
tients, cTnI measured by both assays was consistently
within the normal range. The diagnosis of skeletal myop-
athy was established on biopsy during the course of this
study, and previous diagnoses of acute coronary syndromes
were revised.
The patient with hypothyroid myopathy provided us the
opportunity to study the response of cTnT, cTnI, CK, and
CK-MB to hormone replacement (Table 3). After 6 months
of treatment, levo-thyroxine replacement reversed the clin-
ical signs of myopathy and normalized cTnT, CK, and
CK-MB levels. In contrast, cTnI-Ultra was normal and
barely detectable throughout the study. NT-proBNP was
also normal.
Table 4 charts the chronological development of statin-
induced myopathy in patient #11 and biochemical
response to treatment. Withdrawal of the drug and initiation
of steroid therapy led to gradual clinical improvement and
normalization of CK, CK-MB, and cTnT levels; cTnI-
Ultra and NT-proBNP were normal.
Patient #14 demonstrated that even local chronic injury to
muscledin this case, invasion of thigh muscles by a high-
grade pleiomorphic sarcomadwill cause persistent release
of cTnT, CK, and CK-MB, but not cTnI.
We examined the kinetics of serum cTnT in 21 patients
during 34 separate hospital stays. Data was available on
138 samples taken on different days. Figure 1 illustrates the
proﬁle of serum cTnT in hospitalized patients who had
at least 5 samples assayed on separate days during any 1
admission episode. The maximum percentage change in
cTnT concentration from one day to the next was a median
of 23% (interquartile range: 13% to 33%). The percentage
change between the maximum and minimum values of
cTnT during admission episodes was a median of 30%
(interquartile range: 13% to 56%). Thus, for example, in
patient 11, cTnT dropped maximally by 31% from 0.16 mg/l
Table 2 Clinical Characteristics and Results of Investigations of Individual Patients in Hospitalized Group
Patient #
Age
(yrs)/Sex
Clinical
Presentation
Type of
Myopathy
cTnT (mg/l)
cTnI (mg/l)
CK-MB (mg/l) CK (U/l)
Echo ECG
Coronary
AngiogramMedian Range Period Mean Median Range Period
1 33F Chest pain Alcohol myopathy 0.13 (49) 0.05–0.37 3 yrs <URL (7) 30 (5) 3,732 (49) 1078–12,460 3 yrs Normal Normal (>70) Normal (2)
2 61F Chest pain IMD 0.14 (70) 0.08–0.60 8 yrs <URL (5) 29 (4) 314 (57) 28–708 8 yrs Normal Normal (>50) Normal (3)
3 40F Chest pain PM 0.22 (4) 0.17–0.71 1.5 yrs <URL (3) 1,196 (15) 348–4,115 1.5 yrs Normal Normal Normal
4 77M Chest pain IBM 0.11 (4) 0.11–0.14 1 week <URL (4) 24 (4) 803 (12) 463–1,501 10 yrs Normal ST elevation,
lead I, aVL
SVD
5 71M Chest pain MND 0.05 (14) 0.03–0.06 2 yrs <URL (7) 8 (7) 449 (14) 250–602 6 yrs Normal Normal 3VD
6 65M Chest pain FSHD 0.06 (8) 0.04–0.09 1 week <URL (3) 226 (10) 214–265 4 yrs RWMA
LVEF ¼ 40%
Q waves in
lead III, aVF
3VD
7 51M Chest pain Recurrent
rhabdomyolysis
0.15 (3) 0.10–0.43 4 yrs <URL (2) 31 (3) 3,866 (5) 1,566–6,469 4 yrs Normal Normal NP
8 70F Myalgia Hypothyroid
myopathy
0.08 (5) 0.08–0.10 1 week* <URL (5) 35 (5) 3,595 (5) 4,002–4,641 1 week** Normal Normal Normal
9 52M Chest pain MND 0.03 (5) 0.03–0.04 1 yr <URL (5) 11 (3) 140 (4) 96–219 1 yr LVH LVH NP
10 55M Chest pain Alcohol myopathy 0.14 (16) 0.03–0.30 4 yrs 0.19 (5) 34 (3) 532 (13) 210–892 4 yrs DCM
LVEF ¼ 40%
LBBB/AF Normal
11 74F Back pain Statin myopathy 0.14 (7) 0.11–0.16 1 week <URL (7) 71 (7) 4231 (7) 3,969–5,640 1 week Normal Normal NP
12 27M Headache FSHD 0.03 (2) 2 days <URL (2) 7 (4) 510 (2) 228–800 5 yrs Normal Normal NP
13 67F Falls FSHD 0.06 (2) 2 days <URL (2) 11 (2) 202 (2) 158–245 2 days NP LVH NP
14 48M Thigh swelling Muscle sarcoma 0.04 (5) 0.03–0.07 7 days <URL (5) 5 (5) 380 (5) 296–424 7 days Normal Normal NP
15 65F Chest pain Subclinical 0.07 (11) 0.06–0.12 2 yrs <URL (4) 8 (3) 104 (11) 65–189 2 yrs Normal Normal (>20) Normal (2)
16 74F Myalgia PM 0.22 (4) 0.21–0.25 0.5 yr <URL (4) 106 (2) 4,036 (6) 1,819–5,528 0.5 yr Normal Normal NP
17 78F Acute heart
failure
Statin myopathy 0.19 (9) 0.05–0.23 2 yrs 0.27 (7) 17 (7) 2,656 (9) 1,379–4,960 2 yrs RWMA
LVEF ¼ 40%
Q waves in
lead III, aVF
NP
18 75F Dizzy Spells Statin myopathy 0.12 (3) 0.11–0.14 1 week <URL (3) 67 (3) 9,039 6,521–12,531 1 week Normal Sinus
bradycardia
NP
19 47F Axillary vein
thrombosis
MyoD 0.020 <URL (1) 5 147 Normal Paced rhythm NP
20 87F Chest pain Subclinical 0.03 (5) 0.03–0.04 1 week <URL (5) 8 (4) 181 111–236 1 week Normal AF NP
21 69M Chest infection Sub-clinical 0.05 (2) 0.05–0.05 3 days <URL (2) 15 (2) 1861 892–3,191 15 weeks RWMA
LVEF ¼ 40%
Abnormal NP
22 51M Myalgia Recurrent
rhabdomyolysis
0.06 (21) 0.04–0.10 1 yr <URL (21) 16 (21) 3,084 (21) 48–42,980 1 yr Normal Normal NP
23 42F Myalgia Cocaine abuse 0.13 (4) 0.09–0.14 4 days <URL (4) 17 (3) 1,471 (4) 598–4,800 4 days Normal Normal NP
24 17M Muscle
weakness
Hypokalemic
periodic
paralysis
0.03 (2) 0.5 yr <URL (1) 16 (1) 140–567 1 yr NP Normal NP
25 63M Chest pain Subclinical 0.13 (9) 0.03–0.26 2.5 yrs 0.05 (1) 13 (1) 461 (10) 83–578 2.5 yrs MVR AF Normal (2)
Values in parentheses refer to the number of samples assayed or procedures performed; other values are numbers and ranges. *Before starting thyroxine therapy.
AF ¼ atrial ﬁbrillation; cTnI ¼ cardiac troponin I; cTnT ¼ cardiac troponin T; CK ¼ creatine kinase; CK-MB ¼ creatine kinase myocardial band; DCM ¼ dilated cardiomyopathy; ECG ¼ electrocardiography; FSHD ¼ fascioscapular humeral muscle dystrophy; IBM ¼ inclusion body
myositis; IMD ¼ inﬂammatory muscle disease; LBBB ¼ left bundle branch block; LVEF ¼ left ventricular ejection fraction; LVH ¼ left ventricular hypertrophy; MND ¼ motor neurone disease; MVR ¼ mitral valve replacement; MyoD ¼ myotonic dystrophy; NP ¼ not performed;
PM ¼ polymyositis; RWMA ¼ regional wall motion abnormality; URL ¼ upper reference limit.
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Table 3 Hypothyroid Myopathy and Response to Hormone Replacement Therapy
Day
CK
(U/l)
CK-MB
(mg/l)
cTnT
(mg/l)
cTnI
(mg/l)
NT-proBNP
(pg/ml)
T4
(nmol/l)
TSH
(mU/l)
1–7 3,718* 33* 0.09* <0.01 58* <30 >150
21 1,420 24 0.05 <0.01 61 71
42 475 14 0.03 <0.01 92 39
85 295 9 0.02 <0.01 3
120 212 0.02
157 103 0.02 168 0.11
173 105 0.02 0.49
207 140 0.01 1.0
Values are numbers. Data refers to patient 8. *Mean values of samples analyzed during the ﬁrst week before starting hormone therapy.
NT-proBNP ¼ N-terminal pro-B–type natriuretic peptide; T4 ¼ free thryroxine; TSH ¼ thyroid stimulating hormone; other abbreviations as in Table 2.
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2415on day 1 to 0.11 mg/l on day 2. In this case, 31% was also the
maximal change for the entire episode (Fig. 1). The
maximum absolute change in cTnT concentration from
day to day was a median of 0.02 mg/l (interquartile range:
0.01 to 0.04 mg/l). The maximum change for the entire
episode was a median of 0.03 mg/l (interquartile range: 0.02
to 0.05 mg/l). Figure 2 illustrates the wide variations of
cTnT over several years.
Ten patients had diagnostic skeletal muscle biopsy per-
formed either previously (n ¼ 5) or during the course of this
study (n ¼ 5). Skeletal muscle regeneration was indepen-
dently reported on histology and immunohistochemistry
in 7 patients.
Serum NT-proBNP measured in 15 patients in this group
(56 samples) was a median of 300 pg/ml (interquartile range:
153 to 512 pg/ml).
During the mean and maximum follow-up of 2.4 and 7
years, respectively, none of the patients with elevated cTnT
but normal cTnI sustained any cardiovascular events (AMI,
heart failure, or stroke). Two patients with elevated cTnI
died from stroke and heart failure, respectively. Four
patients died from complications of their underlying
neuromuscular diseases, 1 died of alcohol abuse, and 1 died
of malignancy.Table 4 Development of Statin-Induced Myopathy
Date
cTnT
(mg/l)
cTnI
(mg/l) (U
May 2004 <0.03 2
August 2004 <0.03 2
March 2005
June 2006
September 2006
November 2006
December 2006
August 2007 0.14* <0.01 45
October 2007 0.13 <0.01 54
January 2008 0.05 <0.01 13
October 2008 0.03 <0.01
Data refer to Patient #11 who presented in August 2007. She was swit
Retrospective analysis of blood results indicates rapid onset of skeletal musc
of normal liver enzymes) after starting atorvastatin. *Mean values of sample
Abbreviations as in Tables 2 and 3.Ambulatory patients (n[ 27). This group consisted of 10
patients with Becker muscular dystrophy (BMD), 5 with
limb girdle muscular dystrophy (LGMD), 5 with MyoD, 3
with IBM, 2 with myasthenia gravis (MG), 1 with DMD,
and 1 with Friedreich ataxia (FA). They had no symptoms
other than neuromuscular. Patients with MG and FA were
used as “controls” because these diseases are not character-
ized by CK elevation. Table 5 shows the results of individual
patients. CK (715 U/l; 249 to 1213 U/l) was elevated in 21
patients, CK-MB (18 mg/l; 11 to 28 mg/l) was elevated in 22
of 23 patients tested, and hs-cTnT (0.021 mg/l; 0.011 to
0.038 mg/l) was elevated in 18 patients (7 with BMD, 4 with
LGMD, 3 with IBM, and 4 with MD) . In contrast, cTnI
was normal in all but 1 patient with BMD, who had a minor
elevation. Of the 6 patients (2 with MG, 1 with DMD, 1
with LGMD, 1 with BMD, and 1 with FA) with normal
CK, 5 had normal cTnT. The 2 cTnI assays gave concor-
dant results in all patients tested. NT-proBNP (41 pg/ml;
35 to 97 pg/ml) was normal in all but 2 patients.
ECGs were normal in 15 patients, and there were minor
abnormalities in 3 patients. Echocardiograms were normal
in 11 of 15 patients who had the test. No patient died or
sustained any cardiovascular events during a mean and
maximum follow-up of 2 and 5 years, respectively.and Response to Treatment
CK
/l)
CK-MB
(mg/l)
NT-proBNP
(pg/ml)
AST
(U/l)
26 20
65 38
19
108
176
140
158
70* 71* 38* 109*
82 101
31 22 49
84 4 13
ched from simvastatin 40 mg to atorvastatin 40 mg in April 2006.
le injury (elevation of aspartate aminotransferase [AST] in the presence
s measured on 7 consecutive days.
Figure 1
Kinetics of Serum cTnT in Patients With
Different Types of Neuromuscular Diseases
Although cardiac troponin T (cTnT) is persistently elevated, there are substantial
day to day variations. Patients are numbered according to Table 2.
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Our study shows that patients with neuromuscular diseases
characterized by elevated CK commonly have persistent
elevation of circulating cTnT and CK-MB in the absence
of clinical and cTnI evidence of myocardial injury. They also
have normal NT-proBNP. The totally discordant behavior
of the 2 cardiac troponins contrasts sharply with the con-
cordant pattern generally seen in patients with myocardialFigure 2
Serum Levels of cTnT in Patients With Alcohol-Induced Myo
Over 3 and 7 Years, Respectively
(A) Alcohol-induced myopathy; (B) inﬂammatory muscle disease. Data refer to Patients #injury. cTnT elevation has previously been described in
patients with DMD (21), polymyositis and/or dermatomy-
ositis (22), and IBM (23,24). We show, for the ﬁrst time,
that cTnT elevation is not limited to any speciﬁc skeletal
myopathies, but that it occurs across a wide spectrum of
neuromuscular diseases. Whether the injury is endocrine,
metabolic, autoimmune, genetic, neurally mediated, or
caused by drug toxicity or malignant invasion, the same
characteristic biomarker pattern was observed. Also, it does
not seem to matter whether the insult is systemic or local.
These ﬁndings are in accord with the known biology of
skeletal muscle, whereby regeneration, a recognized source
of cTnT and CK-MB (12–18), is a universal response to any
injury.
We considered elevation of cTnT in our patients to be
a false positive result for myocardial injury, because it
was consistently at variance with the clinical ﬁndings.
This view was strengthened by the demonstration that,
despite persistent release of cTnT into the circulation
over several years, patients had no cardiac symptoms, and
serial ECGs and echocardiograms remained unchanged.
Also, no cardiovascular events occurred, except in 2 pa-
tients with elevated cTnI, and there was no adverse
impact on prognosis during a mean follow-up of 2 years.
Furthermore, the negative results provided independently
by the 2 cTnI assays also indicated absence of myocardial
injury.
Falsely elevated cTnT or cTnI results can sometimes
occur because of assay interference due to pre-analytical
factors (e.g., hemolysis and ﬁbrin clots) and analytical fac-
tors due to heterophile antibodies and human anti-animal
antibodies (25,26). It seems implausible that these inter-
fering factors would be the cause for the positive cTnTpathy and Inﬂammatory Muscle Disease
1 and #2. Abbreviation as in Figure 1.
Table 5 Results of Investigations in Ambulatory Patients
Patient #
Age
(yrs)/Sex Diagnosis CK (U/l)
CK-MB
(mg/l)
hs-cTnT
(mg/l)
cTnI
(mg/l)
NT-ProBNP
(pg/ml) ECG Echo
1 59M BMD 1,040 26 0.013 <URL 38 Normal
2 36F LGMD 1,001 14 0.010 <URL 38 Normal
3 33M BMD 1,153 18 0.023 0.05 (Siemens)
0.28 (Roche)
65 Inverted T in aVL
4 80M IBM 237 19 0.121 <URL 1,305 RBBB Abnormal
5 49M MyoD 312 7 0.045 <URL 31 Normal
6 59M LGMD 2,625 30 0.031 <URL 30 Normal
7a 52M BMD 1,304 28 0.019 <URL 51 RBBB Normal
7b 52M BMD 1,370 30 0.026 <URL 55
8 60M BMD 460 17 0.034 <URL 1,248 Paced Rhythm Abnormal
9 35M LGMD 3,762 39 0.017 <URL 40 Normal Normal
10 35M DMD 70 0.01* Abnormal Abnormal
11 38F FA 52 0.01* Abnormal Abnormal
12 63M MG 185 0.010 Normal
13 40M BMD 784 17 0.015 <URL 47 Inverted T in V 6
14 72M IBM 283 9 0.039 28 Inverted T in aVL
15 73M IBM 593 14 0.113 <URL 97 Normal
16 56M LGMD 110 11 0.100 <URL 35 Normal Normal
17 49M BMD 804 9 0.110 <URL 16 RBBB
18 41M BMD 137 3 0.007 <URL 203 LVH Normal
19 37M MyoD 467 19 0.070 <URL 115 AF Abnormal
20a 47M MyoD 969 11 0.030 <URL 64 Inverted T in V 4-5 Normal
20b 47M MyoD 707 17 0.030 <URL 41 Inverted T in V 4-5 Normal
21 43F MyoD 602 11 0.013 <URL 190 Normal Normal
22 24M MyoD 647 9 0.016 Normal Normal
23 39M BMD 1,678 52 0.024 <URL 23 Normal
24 62M LGMD 2,763 35 0.048 <URL 38 Normal Normal
25 56F MG 139 0.01* Normal Normal
26 40M BMD 1,233 18 0.017 <URL 37 Normal
27 33M BMD 943 23 0.029 <URL 41 Normal Normal
*Standard assay was used. Patients 7 and 20 had blood samples taken at an intervals of 4 and 12 months, respectively.
BMD ¼ Becker muscular dystrophy; DMD ¼ Duchenne muscular dystrophy; FA ¼ Friedreich ataxia; IBM ¼ inclusion body myositis; LGMD ¼ limb girdle muscular dystrophy; MG ¼ myasthenia gravis;
MyoD ¼ myotonic dystrophy; other abbreviations as in Tables 2 and 3.
JACC Vol. 63, No. 22, 2014 Rittoo et al.
June 10, 2014:2411–20 Cardiac Troponin T in Neuromuscular Diseases
2417results obtained in nearly 300 samples in 44 patients in our
study. Similar false negative cTnI results can occasionally be
caused by cTnI autoantibodies (27,28). Because we used 2
different cTnI assays that utilize different capture and
detection antibodies, it is improbable that the negative
results obtained by both assays in our study would be due to
circulating cTnI autoantibodies or any other interfering
antibodies that might exist because of skeletal muscle injury.
False positive and false negative cTn results due to inter-
fering antibodies are rarely encountered in clinical practice,
whereas the systematic discordance of cTnT and cTnI
results that we describe was found to be common and pre-
dictable in patients with neuromuscular diseases. Such
discordance has also been reported by others in patients with
skeletal muscle diseases (21,22,24,29).
It is well recognized that the results of cTnT and cTnI
assays are not quantitatively commutable for a variety
of reasons. Unlike the cTnT assay that has a single manu-
facturer, cTnI assays have several. The cTnI assays are not
standardized and use different antibodies targeting differentepitopes (30,31). After AMI, cTnT and cTnI released into
the circulation exist in multiple molecular forms, including
free forms, degraded fragments, and complexes with other
cTn molecules (32,33). cTnI, in particular, undergoes post-
translational modiﬁcations, such as phosphorylation, oxida-
tion, and proteolytic degradation. These various forms also
appear to be time-dependent after an AMI (34,35). None-
theless, the diagnostic accuracy of cTnT and cTnI assays in
the clinical setting has not been shown to be adversely
affected by these factors (36); hence, the recommendation in
consensus documents to use either assay for the diagnosis of
myocardial infarction (2,4,5). If myocardial injury was pre-
sent in our patients, it would be expected that the 2 cTnI
assays used would be able to detect at least some of, if not all,
the various forms of circulating cTnI.
We showed that the standard and high-sensitivity Roche
cTnT assays gave positive results, whereas both the Siemens
TnI-Ultra and Roche troponin I assays produced negative
results. cTnI was below the detection limit of the Roche
troponin I assay in almost all patients. These same 4 assays
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2418were compared head to head in 718 patients who had
symptoms suggestive of AMI. The diagnostic accuracy of
the cTnI and hs-cTnT assays were found to be equivalent,
and all 3 were superior to the standard cTnT assay for the
early diagnosis of AMI (37). Similar results were found by
other investigators comparing cTnI-Ultra with the standard
cTnT assay (38). We also showed that the cTnI-Ultra assay
yielded concordant results with the standard cTnT assay
when tested in 32 patients with AMI who had cTnT
elevation of the same order of magnitude as that of the
patients with neuromuscular diseases. Three patients in our
study further illustrate that our results cannot be explained
by lack of cTnI assay sensitivity or other analytical factors.
Two patients with co-existent chronic heart failure (and
chronic myocardial injury) had persistent elevation of CK,
CK-MB, cTnT, cTnI, and NT-ProBNP. The third patient
with IBM was admitted with an acute ST-elevation
myocardial infarction. The behavior of cTnT and cTnI
followed the pattern that would be expected of an acute
myocardial injury superimposed on chronic skeletal muscle
injury. During the acute phase, both cTnT and cTnI were
elevated, but a month later, serial cTnI was normal despite
the fact that the cTnT was persistently elevated and was of
similar magnitude as that in the acute phase.
The ﬁrst-generation cTnT assay had signiﬁcant cross
reactivity with skeletal troponin T, a problem that was solved
in the second-generation assay with the use of 2 new car-
diospeciﬁc monoclonal antibodies (39). However, in a
multicenter study led by the inventors of the assay, it was
observed that even this improved assay continued to
register positive results in patients with DMD, although
the frequency was less than that with the ﬁrst-generation
assay (40). The investigators were uncertain whether this
represented subclinical myocardial injury or if the assay
was cross reacting with re-expressed cTnT in diseased
skeletal muscle. Two studies performed shortly afterward
on skeletal muscle biopsies of patients with end-stage
renal disease suggested that the assay would not detect
re-expressed cTnT in diseased skeletal muscle (41,42).
The same antibody pair has been used in subsequent
generations of the assay, including a re-engineered version
of the hs-cTnT assay. The latter’s validation study (20)
did not examine its performance in patients with skel-
etal muscle diseases. We are the ﬁrst group to study the
hs-cTnT assay in patients with neuromuscular diseases.
We believe that elevated cTnT in our patients is due to
the release of re-expressed cTnT from diseased skeletal
muscle into the circulation. This would explain not only the
clinical ﬁndings, normal levels of cTnI and NT-proBNP,
but also the close relationship between cTnT and the 2
well-established markers of persistent skeletal muscle dam-
age, that is, CK and CK-MB. CK-MB and cTnT share
similar ontogenic attributes (10,11,43) that likely explain
their co-existence in diseased skeletal muscle. We also
demonstrated that treatment of patients with reversible
myopathies normalizes cTnT, CK, and CK-MB in unison.Our ﬁndings and conclusions are supported by the recent
work of Jaffe et al. (44), who also showed that patients with
skeletal muscle diseases have elevated cTnT, but normal
cTnI. Furthermore, by using Western blot analysis on
skeletal muscle biopsies obtained from patients with in-
ﬂammatory muscle disease and fascioscapulohumeral dys-
trophy, they demonstrated that the capture and detection
antibodies used in both the standard and hs-cTnT assays are
immunoreactive against proteins of the same molecular
weight as that found in cardiac muscle. No such immuno-
reactivity was found in healthy skeletal muscle. Thus, their
study conﬁrmed that the Roche cTnT assays would give
positive results whether cTnT is from the heart or skeletal
muscle.
One important clinical question is whether the cTnT
assay can be used to diagnose or exclude AMI in patients
with neuromuscular diseases, especially those presenting
with chest pain and nondiagnostic ECGs. The various
criteria (relative and absolute changes in cTn) proposed (45)
to distinguish acute from chronic myocardial injury may not
be applicable to patients releasing cTnT from a noncardiac
source. Any metrics used in patients with neuromuscular
diseases will need to take account of not only analytical
variation, but also the pathobiological variation of cTnT
released from diseased skeletal muscle, which, in turn, will
also depend on the various etiologies. We have shown that
although cTnT is persistently elevated in these patients, the
day to day variation can be substantial in some patients. In
half of the episodes analyzed, the percentage and absolute
daily changes of cTnT exceeded 20% and 20 ng/l, respec-
tively. Further studies are required to determine whether
sampling at shorter intervals (e.g., 2 to 6 hours), as opposed
to our daily measurements, will help to differentiate acute
myocardial injury from the chronic release of cTnT from
diseased skeletal muscle. An added consideration is that
small cTn changes do not necessarily rule out AMI, and
conversely, a relative change of hs-cTnT of >20% appears
to be common in hospitalized patients without AMI
(46,47).
The lack of cardiac speciﬁcity of cTnT could be a possible
explanation for the diagnostic and prognostic differences
between cTnT and cTnI reported recently (48–51). Omland
et al. (48) found hs-cTnT to be abnormally elevated in
10.9% of patients, but hs-cTnI was elevated in only 2.9% of
3,623 patients with stable coronary artery disease and pre-
served left ventricular systolic function. Their correlation was
moderate (r ¼ 0.44), and hs-cTnI, but not hs-cTnT, was
signiﬁcantly and independently associated with both previ-
ous AMI and the incidence of subsequent AMI. Cullen
et al. (49) evaluated hs-cTnT and hs-cTnI assays in 1,571
patients admitted to the emergency department with chest
pain. Both assays had equivalent (94% vs. 96%) sensitivities
for AMI, but the speciﬁcity of hs-cTnT was signiﬁcantly
lower (79% vs. 93%). Ungerer et al. (50) examined the
performance of 3 contemporary cTnI assays (including
cTnI-Ultra) and the cTnT assays in 1,773 patients using
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assays gave discordant results in 3% to 4% of cases. In
contrast, the cTnT assay produced positive results compared
with negative results by the 3 cTnI assays in 14% to 16%
of the samples analyzed. The TIMI (Thrombolysis In
Myocardial Infarction) Study Group compared a hs-cTnI
assay with the fourth-generation cTnT assay in 4,215 pa-
tients with non–ST-elevation myocardial infarction (51).
The 2 assays gave concordant results in 86% of patients.
Interestingly, the less sensitive cTnT assay gave positive
results, whereas the hs-cTnI assay was negative in 11.5% of
patients. These patients also had a low (2.1%) risk of 30-day
cardiovascular death or myocardial infarction compared with
9.2% in hs-cTnI positive patients. One study that compared
hs-cTnT and 2 hs-cTnI assays in patients with acute chest
pain suggested that hs-cTnT is superior to hs-cTnI at
predicting long-term mortality (52).
Study limitations. We have argued that elevation of
circulating cTnT in patients with neuromuscular diseases
originates from diseased skeletal muscle because it is a
known source for it, and clinical and biochemical testing
with cTnI and NT-proBNP showed no evidence of myo-
cardial injury or stress. Skeletal muscle biopsies in our study
were done for diagnostic purposes only. We made no
attempt to try and identify cTnT expression in biopsy
specimens. As indicated, such a study has now been per-
formed by Jaffe et al. (44).
The concentration of elevated hs-cTnT was relatively low
(<30 ng/l) in some of our patients. Although most of them
had normal ECGs, echocardiograms, and NT-proBNP
levels, it might have been preferable to use a hs-cTnI assay
to exclude myocardial injury in this group of patients. The
chronic release of low levels of cTn from the myocardium,
however, is associated with major structural heart diseases,
such as dilated and hypertrophic cardiomyopathies and
inﬁltrative diseases of the myocardium. These patients
almost invariably have markedly abnormal ECGs, echocar-
diograms, and NT-proBNP.
Our study was not designed to answer the question of
how frequently cTnT from diseased skeletal muscle could
confound the diagnosis of myocardial injury in patients
attending the emergency department with suspected acute
coronary syndromes. Nonetheless, we believe that the
number of patients affected is likely to be signiﬁcant. We
have shown that cTnT elevation occurs in skeletal muscle
diseases of diverse etiologies. In addition to patients with
well-known neuromuscular diseases, there are large
numbers of individuals who are taking statins or abuse
alcohol and recreational drugs. Furthermore, some patients
have subclinical skeletal muscle diseases, which we diag-
nosed only through routine CK testing. Also, the use of
the hs-cTnT assay will identify additional patients with
low levels of cTnT from skeletal muscle that would not
have been detected by the standard assay. One study of the
causes of cTnT elevation in patients admitted to a secondary
care hospital found an association with neuromusculardiseases in 6.3% (53). Lin et al. found cTnI to be negative
and CK-MB positive in 8.8% of 1,719 patients with sus-
pected myocardial infarction, which was ascribed to skeletal
muscle diseases (54).
Conclusions
The biological differences in tissue expression between
cTnT and cTnI have important clinical implications. Pa-
tients with neuromuscular diseases of diverse etiologies
commonly have persistent elevation of cTnT and CK-MB
without clinical or cTnI evidence of myocardial injury.
The cTnT detected by the commercial assay in the circu-
lation of these patients likely represents re-expressed cTnT
released from diseased skeletal muscle. Further studies are
required to determine the impact of these new ﬁndings on
the diagnosis of myocardial infarction in unselected patients
presenting to the emergency department with symptoms
suggestive of acute coronary syndromes.
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